MBX Biosciences, Inc. Common Stock (MBX) — Stock Valuation & Research

MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for individuals suffering from chronic hypoparathyroidism. The company is also progressing with MBX 1416, a prolonged-action glucagon-like peptide-1 (GLP-1) receptor antagonist, which is undergoing Phase 1…

MBX key statistics

Price$55.69
Market cap$2.68B
SectorHealthcare
IndustryBiotechnology
ExchangeNASDAQ
52-week range20.27-72.64
Beta0.1

Explore MBX's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.